












































Alzheimer’s disease (AD) is a primary progressive 
neurodegenerative disease where the aberrant meta-
bolism of the amyloid precursor protein (APP) and the 
production and deposition of beta-amyloid peptide (Aβ) 
are considered responsible for neuronal death [1]. A 
putative link between the tumor suppressor p53 and the 
perturbation of APP metabolism has been demonstrated. 














































p53, independent from point mutations, has been 
reported in tissues from patients with AD that led to an 
impaired and dysfunctional response to stressors [2-4]. 
One of the activators that induces p53 posttranslational 
modification and wild-type conformational stability is 
homeodomain-interacting protein kinase 2 (HIPK2) [5]. 
Here we discuss about the potential relevance of the 
definition of HIPK2 as a target for AD and highlight the 
existence of a novel amyloid-based pathogenetic 
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dysfunctional cells. 
 
Alzheimer’s disease and beta-amyloid 
 
Beta-amyloid in AD is the result of the proteolytic 
metabolism of APP, an integral cell membrane 
glycoprotein of 697-770 residues which is the substrate 
of three proteolytic enzymes in two alternative 
pathways mutually in equilibrium [6]. In the non-
amyloidogenic pathway, a protease, named α-secretase, 
cleaves APP in the extracellular domain and releases the 
ectodomain of APP (soluble APPα) into the 
extracellular space, thus precluding Aβ formation. 
Otherwise, in the amyloidogenic pathway, Aβ is formed 
following cleavage by β and γ secretases, that cleave the 
N and C terminus of Aβ, respectively (Figure 1). The 
two main isoforms found in AD brains are Aβ 1-40 and 
Aβ 1-42. Physiologically the 40-amino-acid long 
peptide is the most abundant form [7-9], since the 


































Aβ 1-40 [10]. For these reasons, Aβ1-40 and Aβ1-42 
may have different biological actions [11] and the ratio 
of their production may be altered in pathological 
conditions, such as in familial AD [12].  
 
Although the direct and the indirect neurotoxic role of 
Aβ are unchallenged (for an exhaustive review see 
[13]), recent findings suggest that the peptide may have 
so far unforeseen physiological roles [14]. Besides its 
presence in AD brains, experimental evidence indicated 
that Aβ peptides are produced constitutively by all cells, 
including neurons, and are found in the nM-pM range in 
the CSF of non-demented individuals [15] and in media 
from neuronal and non-neuronal cell cultures [16, 17], 
thus suggesting that, as well as having a potential 
pathological role in AD, Aβ peptides under normal 
conditions may have a role in the regulation of 
physiological functions, consistent with their ubiquitous 
presence and normal synthesis. We will discuss here on 
how Aβ may have a role in the regulation of the 
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neurodegeneration 
 
From its discovery in 1979 [18], p53 continues to 
fascinate scientists and it is still nowadays one of the 
most extensively studied protein. Such interest is due to 
the key role of p53 in the prevention of cancer so as to 
be defined the “guardian of the genome” [19]. However, 
activities of p53 might have a role not only in regulating 
cancer progression, but also in the control of other 
aspects of health and disease such as development, 
aging and metabolism [20]. p53 exerts its main 
biological role of tumor suppressor and master 
controller of the genomic integrity especially acting as 
transcription factor [21]. p53 oversees the correct 
implementation of processes and it intervenes only in 
case of dangerous deviations from the proper cellular 
activity. When the cell is exposed to critical conditions 
or undergoes damages p53 arbitrates cell faith [22]. 
Loss of p53 or deregulation of its activities leads not 
only to cancer but also to cardiovascular, metabolic 
diseases, neurodegeneration and to the process of aging, 
because of the great number of p53-regulated genes 
which underlie all these different biological events [23] 
(see Table 1). 
 
The very first signal which stimulates p53 activity is the  



























constitute a danger to the genomic integrity of cells 
such as oxidative stress, DNA damage, hypoxia, 
oncogene activation, telomere erosion, changes in 
metabolism, unusual prolongation of some signaling 
pathways and local depletion of nutrients, among others 
[41]. Immediately after these damages p53 is the 
substrate of a great number of possible post-
translational modifications introduced by a variety of 
specific enzyme systems [42]. These alterations 
comprise a large network of covalent changes inducing 
characteristic modifications within the protein quantity, 
activity and ability to interact or cooperate with a 
variety of other proteins [43]. The delicate balance 
between p53 Structure and Activity Relationship (SAR) 
can be disrupted even by a single amino acid 
substitution within the DNA binding domain (DBD) 
which is sufficient to limit or abolish the capacity of 
p53 to direct sequence-specific transcriptional activity 
[44]. This is the case of the majority of human cancers 
in which missense mutations in the DBD result in an 
altered network which can affect the prognosis. Beside 
gene mutation, p53 activity could be impaired also as 
consequence to a conformational change. p53 may lose 
its transcriptional activity due to an unfolded tertiary 
structure which determines a reduction in its affinity for 
specific DNA target sequence. Recent observations 
confirm that p53 structure changes can play a central 





































 target  
Cellular stress   Molecule  
modifier  
p53 residue and type 
 of modification 
Reference  
Cell cycle  p21  Mild DNA damage  PCAF  Lys320-Acetylation  24 
checkpoint   Gadd45  Mild DNA damage  E4F1  Lys320-Ubiquitylation  25 
    UV radiation  CK2  Ser392-Phosphorylation  26, 27 
Apoptosis   Transactivation: Bax,   Severe DNA damage  HIPK2  Ser46-Phosphorylation  28, 29, 30, 31 
  Bcl-X1, Apaf-1, Fas,   Severe DNA damage  CBP  Lys382-Acetylation  28 
  Bad, Noxa, Puma  UV radiation  MAPK  Ser46-Phosphorylation  32 
  Transrepression: Bcl-2,  Genotoxic stress  DYRK2  Ser46-Phosphorylation  33 
  Bcl-X1, Survivin  Genotoxic stress  PKCδ Ser46-Phosphorylation  34 
    Severe DNA damage  MOF and TIP60  Lys120-Acetylation  35, 36 
    Severe DNA damage  p300  Ls373-Acetylation  37 
Senescence   p21  DNA damage  PML IV  Lys382-Phosphorylation  38 
  p66  DNA damage  PML IV  Ser20-Phosphorylation  38 
    Senescence stresses  ATM/Chk2  Ser15, Ser20-Phosphorylation  32, 39 
    Senescence stresses  ATR/Chk1  Ser15, Ser37-Phosphorylation  32, 39, 40 
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determining organism aging when its activity is 
increased, p53 can promote selected aspects of the 
aging process. Different studies indicate a delicate 
balance between the tumor suppressive and age-
promoting functions of p53. In several mouse models 
and also from human population studies, alteration of 
p53 activity has been demonstrated to influence the 
comparison of premature/accelerate aging under some 
circumstances (such as stress) or otherwise induce 
tumor suppression [47-52]. Evidence in mice and 
humans suggest that p53 acts as a longevity-assurance 
gene, basically reducing the influence of tumorigenesis 
[53, 54]. Our group has studied p53 in fibroblasts from 
aged controls and demented patients finding that with 
aging there is an increase in the expression of an 
unfolded protein state, which is more pronounced in AD 
patients and is not dependent on gene mutations [55]. 
As a result of such conformational change, p53 partially 
loses its activity and shows a significant impairment in 
its DNA binding and transcriptional capacity when cells 
are exposed to a noxious stimulus [55]. In fact, AD 
fibroblasts are less vulnerable to oxidative injury than 
fibroblasts from non-AD subjects to the point that 
conformationally altered p53 has been proposed as 
putative biomarker for early AD [55]. This altered 
conformation can be due to a loss of zinc (Zn
2+) ion in 
the core domain of the protein, that provides the basic 
scaffold for the DNA binding and which has been 
demonstrated to be crucial for the stabilization of p53 in 
the so called “wild-type” folded form. Exposure of 
wild-type p53 (wt53) to metal chelators such as 
ethylenediaminetetraacetic acid (EDTA) or ortho-
phenanthroline determines a rapid switch to the 
unfolded form positive to an antibody (clone PAb240), 
recognizing a primary epitope cryptic in wt53 [56]. 
Upon addiction of micromolar amounts of Zn
2+, the 
protein undergoes a refolding to the native form and 
reacquires DNA-binding competence [56].  Trying to 
investigate the cause of this alteration we found that the 
exposure to nanomolar concentrations of the beta-
amyloid peptide 1-40 (Aβ 1-40) induced the expression 
of the unfolded p53 protein isoform in fibroblasts 
derived from non-AD subjects [3]. These data suggested 
that the tertiary structure of p53 and the sensitivity to 
p53-dependent apoptosis is influenced by low 
concentrations of soluble Aβ. On this basis, we assumed 
that low amounts of soluble Aβ  induce early 
pathological changes at cellular level that may precede 
the amyloidogenic cascade and one of these changes is 
the induction of the unfolded state of p53, suggesting a 
role of the protein in the early pathogenesis of AD [3]. 
Recently, in cultured peripheral blood cells derived 
from AD patients we and others observed a detectable 
amount of unfolded p53, recognized with the antibody 
PAb240, which made these cells distinct from those of 
controls. We suggest that unfolded p53 could be used as 
a biomarker of the disease also in early stages [57, 58]. 
Zhou and collaborators speculate that unfolded p53 
might be the responsible for the failure of G1/S 
transition checkpoint in AD lymphocytes, which is 
normally mediated by wt53, connecting unfolded p53 to 
a peripheral event associated to the disease. They 
suggest that the cause of p53 conformational change 
could be oxidative stress, Aβ toxicity and the effects of 
oxygen free radicals [59]. This additional observation 
about the existence of an altered state of p53 at the 
peripheral level in subjects with AD reinforces the 
hypothesis that the protein can have a role in the 
pathogenesis of the neurodegenerative disease. 
However, further studies are needed to understand the 
causes of such conformational change and, as 
consequence, about how unfolded p53 contributes to the 
progress of age and neurodegeneration.  
 
Misfolded p53 and the role of HIPK2 
 
Homeodomain-interacting protein kinase 2 (HIPK2) is a 
member of a novel family of nuclear serine/threonine 
kinases that localizes into the nuclear bodies and acts as 
co-repressor for several transcription factors [60]. 
Furthermore, one important function of HIPK2 is the 
apoptotic activation of p53 in response to genotoxic 
agents [5]. HIPK2 interacts physically and functionally 
with p53 phosphorylating it at Serine 46 (Ser46) for 
apoptotic activation (Table 1) [28-31]. HIPK2 interacts 
also with the acetyltransferase CREB binding protein 
(CBP) and co-localizes with CBP and p53 at 
promyelocytic leukemia nuclear bodies (PML-NBs); 
here HIPK2-mediated p53Ser46 phosphorylation 
enhances CBP-mediated p53 acetylation at Lys382, 
potentiating the expression of pro-apoptotic target genes 
[28]. Thus, although Ser46 can be phosphorylated by 
additional kinase other than HIPK2, including ATM 
[61], DNA-dependent protein kinase (DNA-PK) [62], 
protein kinase C δ (PKCδ) [63], and dual-specificity 
tyrosine-phosphorylation-regulated kinase 2 (DYRK2) 
[64], the fact that only HIPK2 can drive Lys382 
acetylation renders this kinase a unique and complex 
regulator of p53 apoptotic function. Thus, in the 
absence of HIPK2, the lack of Lys382 acetylation 
strongly impairs p53 pro-apoptotic activation [65]. 
HIPK2 function is important for the p53 
acetylation/deacetylation balance by regulating the 
activity of deacetylase Sirt1, through repression of 
NADPH oxidase 1 (Nox1) [66]. Thus, in the absence of 
HIPK2, oxygen reactive species (ROS) are induced in 
cancer cells, with activation of Nox1 and Sirt1 activities 
that inhibit p53 apoptotic activity in response to DNA 
damage [66]. 
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involves also wt53 protein conformation. In the absence 
of HIPK2, p53 acquires a misfolded conformation 
loosing DNA binding and transcriptional activities, 
depending on deregulation of metallothioneins and Zn
2+ 
[67, 68]. Thus, Zn
2+ supplementation to HIPK2 depleted 
cancer cells determines a regain of the wt53 protein 
conformation and restoration of DNA binding and 
transcriptional activities in response to genotoxic agents 
in vitro and in vivo [67]. Treatment of mice carrying 
tumors derived from HIPK2-depleted cells with a 
combination of Zn
2+  and chemotherapeutic drug 
Adriamycin enhances growth suppression of such 
tumors  in vivo [67]. From these data it appears that 
HIPK2 plays a major role in the regulation of p53 
function through the switch between p53 dynamic 
conformational states, and that Zn
2+  is a fundamental 
cofactor. 
 
The binding and exchange/transport of Zn
2+, as well as 
of other heavy metals, such as cadmium or copper, are 
modulated by metallothionein (MT), a family of at least 
10 highly conserved, low molecular weight cystein-rich 
metalloproteins [69]. The interest in MTs derives from 
their role as regulators of p53 folding and activity, since 
small amount of MTs can induce p53 activity regulating 
the folding of the DBD domain through Zn
2+ 
modulation, whereas excess of MTs reduces p53 
activity by exerting their Zn
2+ chelator function [70, 71]. 
Furthermore, an increase of MTs expression also 
correlates with chemoresistance, increased cell 
proliferation, reduced apoptosis and inhibition of p53 
activity in various human tumors [72]. In this regard, it 
has been shown that HIPK2 negatively regulates MT2A 
gene, whose mRNA transcript isoform appears to be 
associated with cell proliferation in invasive ductal 
cancer tissues and that, on the contrary, HIPK2 
depletion correlates with MT2A up-regulation in MCF7 
breast cancer cells [68]. Moreover, MT2A depletion by  
siRNA (silencing RNA) in cells depleted of HIPK2, 
restores wt53 conformation [68].  
 
HIPK2 inactive/active switch in Alzheimer’s disease 
and the relevance of zinc supplementation 
 
Given the role of HIPK2 in maintaining wt53 
conformation in tumor cells and the presence of an 
unfolded state of p53 in AD peripheral cells, the interest 
of a putative modulation of HIPK2 in AD type dementia 
has been investigated. As reported above, the exposure 
to nanomolar concentrations of Aβ led to an increased 
content of unfolded p53 protein in fibroblasts from AD 
patients, compared to control subjects [3]. Looking at 
the molecular mechanism of p53 misfolding, a link 
among Aβ, p53 and HIPK2 in the neuropathology may 
be proposed [73]. Aβ has been hypothesized to be 
responsible for HIPK2 proteasomal degradation, in turn 
resulting in HIPK2 nuclear disappearance from target 
promoters such as hypoxia inducible factor 1α (HIF-1α) 
[74] and MT2A [68], whose mRNA was found up-
regulated in cellular models of AD [73]. The induction 
of MT2A, depending on HIPK2 knockdown, has been 
reported to be responsible for p53 misfolding and 
inhibition of p53 transcriptional activity [68]. On this 
basis, we could speculate that, in AD, HIPK2 
deregulation might be involved in p53 misfolding, most 
likely through MT2A upregulation. Data from literature 
point out that MTs play a very important role in 
controlling Zn
2+  homeostasis. Increased MTs levels 
induce down-regulation of many biological functions 
related to Zn
2+, such as metabolism, gene expression 
and signal transduction [75]. The MTs can serve as a 
source of Zn
2+
 and are considered also as strong anti-
oxidants and protective factors against stress conditions 
[76]. MTs are highly expressed in both astrocytes and 
hippocampal neurons in the aging brain and are a key 
area of investigation for inflammation and modulation 
of Zn
2+ availability in the aging brain [77]. Therefore 
these proteins are being intensively studied in the 
context of aging and longevity mechanisms [78]. 
During aging there is an increased expression of MTs 
mRNA but decreased levels are found in healthy 
centenarians, indicating a possible selection for survival 
of low expressors [79]. However the precise function of 
these proteins in aging is still debated, because their 
protective role could also be deleterious in the case of 
sequestration of Zn
2+ as observed both in human aging 
and AD [73, 80, 81]. The high MTs mRNA in 
lymphocytes from old people and Down syndrome 
subjects and the low MTs mRNA in lymphocytes from 
young adult and centenarians are a significant support to 
the idea of a pleiotropic role of MTs in aging [82]. 
Therefore, the role of HIPK2 in MT2A regulation could 
unveil interesting interplay between these molecules 
with p53 also in other chronic diseases such as AD. 
Taking into account MT2A upregulation dependent on 
HIPK2 depletion, zinc supplementation to hypoxia-
treated cancer cells reestablishes HIPK2 nuclear 
localization and DNA binding activity, restoring p53 
apoptotic function in response to anticancer drug [83]. 
Similarly, zinc-supplementation to AD cellular models 
restores HIPK2 DNA binding, p53 wild-type 
conformation and apoptotic activity in response to a 
genotoxic agent [73]. Hence, we could define that, in 
AD, HIPK2 plays a critical role in maintaining p53 
wild-type conformation indirectly through MT2A down 
regulation, and that Zn
2+ is a fundamental cofactor. 
 
On the basis of data here summarized, we speculate that 
soluble Aβ may be responsible for important modula- 
   





































tory effects at cellular level before triggering the 
amyloidogenic cascade. One of these modulatory 
effects may be the inhibition of HIPK2 activity, with 
MT2A upregulation, in turn responsible for the 
induction of an altered conformational state of p53. As a 
result of this conformational change, p53 looses its 
transcriptional activity and is unable to properly activate 
an apoptotic program when cells are exposed to a 
noxious stimulus. Altogether, Aβ-induces HIPK2 
depletion and the consequent unfolded p53 may 
contribute to AD pathogenesis leading to dysfunctional 




In humans, aging may be influenced by the balance of 
cell survival versus cell death, a decision at least in part 






































DNA integrity and correct repair [84]. We focused 
mainly on one of such proteins, p53, recently shown to 
be involved in aging and AD [55, 57, 58]. A link 
between AD pathology and an unfolded state of p53 has 
been proposed, based on findings that with aging an 
increase of unfolded p53 occurs in healthy subjects and 
is peculiarly high in AD patients. By investigating what 
could be the contribution of a conformational change of 
p53 to AD pathogenesis, for the first time we define a 
hierarchical scale of events driven by Aβ: Aβ-induced 
HIPK2 depletion and unfolded p53 may contribute to 
AD pathogenesis leading to dysfunctional cells [73]. 
This observation is intriguing in light of recent data 
showing that p53 suppresses cellular aging. In this 
context, despite the well-known capability of p53 to 
induce senescence, more recent evidence demonstrated 
that p53 can also act as a suppressor of cellular 
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that p53 regulates cell growth and metabolic stress 
through different pathways [86]. One of these is 
represented by mTOR pathway, which is strictly 
connected with organismal aging, as its inhibition may 
be one of the main mechanisms decreasing lifespan 
[87]. p53 is able to regulate activity of mTOR following 
DNA damage or oncogenic stress by activation of 
specific effectors (PTEN, AMP kinase and TSC-2), 
each of which signals to diminish the activity of mTOR, 
which is involved in senescent phenotype [85, 88]. By 
suppressing mTOR, p53 can suppress senescent 
phenotype, converting senescence into quiescence [89]. 
Furthermore, mTOR inhibition induces  autophagy, thus 
resulting in the accumulation of protein aggregates, 
endoplasmic reticulum stress and mitochondrial 
dysfunction, each of which could promote senescence 
[86]. Thus, taking into account that with aging an 
increase of unfolded p53 occurs, the loss of wild-type 
p53 conformation could free mTOR, thus inducing 
aging-associated abnormalities. 
 
Thirty years have passed since p53 discovery and in 
these decades a lot of information about its structure, 
functions and pathways has been achieved. In the fourth 
decade of p53 investigation the research community 
hopes to be able to get new drugs to affect p53 function 
to treat not only cancer but also important neurological 
conditions, such as AD. The recognition of HIPK2 as 
new target of the effect of Aβ could suggest a new 
putative functional biomarker useful in addressing new 




This work was supported by the contribution of grants 
from the Ministry of University and Research (MIUR, 
Grant #2007HJCCSF to S.G.), by the UNIPV-Regione 
Lombardia and grant from Italian Association for 
Cancer Research (AIRC) to G.D.O. 
 
CONFLICT OF INTERESTS STATEMENT 
 




IARC (International Agency for Cancer Research) TP53 




1.  Hardy  J,  Selkoe  DJ.  The  amyloid  hypothesis  of  Alzheimer’s 
disease:  progress  and  problems  on  the  road  to  therapeutics. 
Science. 2002; 297:353‐356. 
2. Uberti D, Carsana T, Bernardi E, Rodella L, Grigolato P, Lanni C, 
Racchi  M,  Govoni  S,  Memo  M.  Selective  impairment  of  p53‐








p53  conformational  state  and  protects  against  doxorubicin.  J 
Neurochem. 2007; 103:322‐333. 
5. Puca R, Nardinocchi L, Givol D, D’Orazi G. Regulation of p53 
activity  by  HIPK2:  molecular  mechanisms  and  therapeutical  im‐
plications in human cancer cells. Oncogene. 2010; 29:4378‐4387. 
6.  Nunan  J,  Small  DH.  Regulation  of  APP  cleavage  by  alpha‐, 
beta‐and gamma‐secretases. FEBS Lett. 2000; 483:6‐10. 




Yamaguchi  T.  Amyloid‐deposits  in  transgenic  mice  expressing 
human β amyloid  precursor  protein  have  the  same 








11.  Zou  K,  Kim  D,  Kakio  A,  Byun  K,  Gong  JS,  Kim  J,  Kim  M, 
Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, 










14.  Mura  E,  Lanni  C,  Preda  S,  Pistoia  F,  Sarà  M,  Racchi  M, 
Schettini G, Marchi M, Govoni S. beta‐Amyloid: a disease target 
or  a  synaptic  regulator  affecting  age‐related  neurotransmitter 
changes? Curr Pharm Des. 2010; 16:672‐683. 
15.  Selkoe  DJ,  Schenk  D.  Alzheimer’s  disease:  molecular 

























24.  Barlev  NA,  Liu  L,  Chehab  NH,  Mansfield  K,  Harris  KG, 
Halazonetis  TD,  Berger  SL.  Acetylation  of  p53  activates 




C.  E4F1  is  an  atypical  ubiquitin  ligase  that  modulates  p53 
effector  functions  independently  of  degradation.  Cell.  2006; 
127:775–88. 
26. Milne DM, Palmer RH, Meek DW. Mutation of the casein 
kinase  II  phosphorylation  site  abolishes  the  anti‐proliferative 
activity of p53. Nucleic Acids Res. 1992; 20:5565‐5570. 












30.  Di  Stefano  V,  Rinaldo  C,  Sacchi  A,  Soddu  S,  D’Orazi  G. 
Homeodomain‐interacting  protein  kinase‐2  activity  and  p53 
phosphorylation  are  critical  events  for  cisplatin‐mediated 
apoptosis. Exp Cell Res. 2004; 293:311‐320. 
31. Pistritto G, Puca R, Nardinocchi L, Sacchi A, D’Orazi G. HIPK2‐
induced  p53Ser46  phosphorylation  activates  the  KILLER/DR5‐
mediated caspase‐8 extrinsic apoptotic pathway. Cell Death and 
Differentiation. 2007; 14:1837‐1839. 




Targeted  to  the  Nucleus  and  Controls  p53  via  Ser46 









of  p53  modulates  the  decision  between  cell‐cycle  arrest  and 
apoptosis. Mol. Cell. 2006; 24:827‐839.  
37. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, 
Swartzbeck  A,  Quong  AA,  Zhang  X,  Beerman  T,  Pestell  RG, 
Avantaggiati ML. Distinct p53 acetylation cassettes differentially 





39.  Qian  Y,  Chen  X.  Tumor  suppression  by  p53:  making  cells 
senescent. Histol Histopathol. 2010; 25:515‐526. 
40.  Toledo  LI,  Murga  M,  Gutierrez‐Martinez  P,  Soria  R, 
Fernandez‐Capetillo  O.  ATR  signaling  can  drive  cells  into 
senescence  in  the  absence  of  DNA  breaks.  Genes  Dev.  2008; 
22:297‐302. 
































T,  Sutherland  A,  Thorner  M,  Scrable  H.  Modulation  of 
mammalian life span by the short isoform of p53. Genes Dev. 
2004; 18:306‐319. 
50.  Varela  I,  Cadiñanos  J,  Pendás  AM,  Gutiérrez‐Fernández  A, 
Folgueras  AR,  Sánchez  LM,  Zhou  Z,  Rodríguez  FJ,  Stewart  CL, 













damage  protection  by  the  Arf/p53  pathway.  Nature.  2007; 
448:375‐379. 
54.  Feng  Z,  Hu  W,  Teresky  AK,  Hernando  E,  Cordon‐Cardo  C, 
Levine AJ. Declining p53 function in the aging process: A possible 
   
www.impactaging.com                   552                                  AGING,   September 2010, Vol.2 No.9mechanism  for  the  increased  tumor  incidence  in  older 
populations. PNAS. 2007; 104:16633‐16638. 
55. Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi 
M,  Govoni  S,  Memo  M.  Identification  of  a  mutant‐like 
conformation  of  p53  in  fibroblasts  from  sporadic  Alzheimer’s 
disease patients. Neurobiology of Aging. 2006; 27:1193‐1201. 
56.  Mèplan  C,  Richard  MJ,  Hainaut  P.  Redox  Signalling  and 
Transition Metals in the Control of the p53 Pathway. Biochem 
Pharmacol. 2000;  59:25‐33. 

















Appella  E,  Anderson  CW.  ATM  mediates  phosphorylation  at 
multiple  p53  sites,  including  Ser46,  in  response  to  ionozing 
radiation. J Biol Chem. 2002; 277:12491‐12494. 
62. Komiyama S, Taniguchi S, Matsumotot Y, Tsunoda E, Ohto T, 
Suzuki  Y.  Potentiality  of  DNA‐dependent  protein  kinase  to 
phosphorylate  Ser46  of  human  p53.  Biochem  Biophys  Res 
Commun. 2004; 323:816‐822. 
63. Yoshida K, Liu H, Miki Y. Protein kinase C δ regulates Ser46 
phoshorylation  of  p53  tumor  suppressor  in  the  apoptotic 
response to DNA damage. J Biol Chem. 2006; 281:5734‐5740. 
64. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is 




G.  HIPK2  modulates  p53  activity  towards  pro‐apoptotic 
transcription. Mol Cancer. 2009; 8:1‐14. 
66. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol 
D,  D’Orazi  G.  Nox1  is  involved  in  p53  deacetylation  and 
suppressio of its transcriptional activity and apoptosis. Free Rad 
Biol Med. 2010; 48:1338‐1346. 
67.  Puca  R,  Nardinocchi  L,  Gal  H,  Rechavi  G,  Amariglio  N, 
Domany  E,  Notterman  DA,  Scarsella  M,  Leonetti  C,  Sacchi  A, 
Blandino G, Givol D, D'Orazi G. Reversibile dysfunction of wild‐















after  exposure  to  metal  chelators  in  vitro  and  in  intact  cells. 
Oncogene. 2000; 19:5227‐5236. 
72. Cherian MG, Jayasurya A, Bay BH. Metallothioneis in human 
tumors  and  potential  roles  in  carcinogenesis.  Mut  Res.  2003; 
533:201‐209.  
73. Lanni C, Nardinocchi L, Puca R, Stanga S, Uberti D, Memo M, 




74.  Nardinocchi  L,  Puca  R,  Guidolin  D,  Belloni  AS,  Bossi  G, 















Ottaviani  E,  De  Benedectis  G.  Inflamm‐aging.  An  evolutinary 
perspective  on  immunosenescence.  Ann  NY  Acad  Sci.  2000; 
908:244‐254. 
79. Moccheggiani E, Costarelli L, Giacconi R, Cipriano C, Muti E, 
Malavolta  M.  Zinc‐binding  proteins  (metallothionein  and α ‐ 2 
macroglobulin)  and  immunosenescence.  Experimental 
gerontology. 2006; 41:1094‐1107. 
80.  Moccheggiani  E,  Muzzioli  M,  Giacconi  R.  Zinc  and 




82. Malavolta  M, Cipriano C,  Costarelli L, Giacconi  R, Larbi A, 
Pawelec  G,  Dedoussis  G,  Herbein  G,  Monti  D,  Jajte  J,  Rink  L, 
Moccheggiani  E.  Metallothionein  down‐regulation  in  very  old 




interacting  protein‐kinase  2  and  p53  activity  and  suppressing 
HIF‐1α. PLoS_One. 2009; 4:e6819. 
84.  Francisconi  S,  Codenotti  M,  Ferrari‐Toninelli  G,  Uberti  D, 
Memo  M.  Preservation  of  DNA  integrity  and  neuronal 
degeneration. Brain Res Brain Res Rev. 2005; 48:347‐351. 






















www.impactaging.com                   554                                  AGING, September 2010, Vol.2 No.9